Navrogen provides Research and Development services for its business partners to advance clinical product candidates for the treatment of various cancers. Current pipeline is shown below.
Navrogen’s technology platforms enable us to discover and assemble a database of tumor types that produce or induce factors that suppress humoral immunity against cancer cells. Humoral immunity against cancer cells is referred to as humoral immuno oncology (HIO), which is mediated by antibodies and the complement system. Navrogen is leveraging its screening assays to identify HIO suppressive factors to assemble a pipeline of therapeutic agents that are refractory to these tumor produced factors. The combination of HIO tumor classification database along with our proprietary agents are yielding a new class of anti-cancer therapies that address an area of oncology with unmet medical need that will bring differentiated therapeutic options to patients affected with HIO-suppressed tumor types.